|Bid||53.51 x 800|
|Ask||53.49 x 2200|
|Day's Range||46.19 - 54.06|
|52 Week Range||41.33 - 277.80|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.67|
Subscribe to Yahoo Finance Plus to view Fair Value for NVAX
The White House on Thursday announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S., cautioning that COVID-19 cases are likely to continue to climb over the summer travel season.
The company's protein-based shot has been authorized or approved in several other countries, including the U.K. and Singapore.
Novavax (NASDAQ: NVAX) is very late to the party in entering the COVID-19 vaccine market. Wall Street analysts are extremely pessimistic about the stock. Novavax definitely is late in entering the COVID-19 vaccine market and still hasn't won authorization for its vaccine in the U.S. Novavax's shares really have sunk like a brick since the fourth quarter of 2021.